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Abstract 
Evolutionary pressure has produced an “arms race” between cellular restriction factors 
(limiting viral replication) and viral proteins (overcoming host restriction). The host factors 
SAMHD1 and SLFN1 patrol metabolic bottlenecks required for HIV replication. Conversely, 
the HIV accessory proteins Vpx, Vpu and Nef manipulate cellular metabolism to enable viral 
replication. Recent work identifying Vpu-mediated downregulation of the alanine transporter 
SNAT1 and Nef-mediated downregulation of the serine carriers SERINC3/5 has uncovered 
the importance of HIV manipulation of the amino acid supply. Interference with CD4+ T-cell 
amino acid metabolism suggests a novel paradigm of viral immunomodulation, and 
signposts fundamental aspects of lymphocyte biology.  
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Introduction 
Human Immunodeficiency Virus (HIV) infects almost 40 million people worldwide and causes 
more than 1 million AIDS-related deaths every year (latest data available from 
www.unaids.org). In addition to the Gag, Pol and Env polyproteins common to all 
retroviruses, HIV encodes the so-called “accessory proteins” Vif, Vpr, Nef and Vpu/Vpx, 
dispensable for viral replication in vitro, but essential for viral pathogenesis in vivo (Figure 1; 
reviewed in [1]). Vif, Vpr and Nef are common to all strains of HIV, but Vpu is found only in 
HIV-1 (responsible for the global AIDS pandemic), and Vpx is found only in HIV-2 
(responsible for a minority of infections, particularly in West Africa). As well as counteracting 
host-cell restriction and promoting immune evasion (reviewed in [2]), recent results suggest 
that HIV accessory proteins directly manipulate cellular metabolic pathways to optimise the 
intracellular environment for productive infection (Figure 2). They are therefore accomplices, 
rather than accessories to the crime. 
Whilst all viruses co-opt cellular metabolism to enable their replication, two characteristics of 
HIV infection in vivo present specific challenges. First, like all retroviruses, HIV relies on 
reverse transcription for replication of its genome. Second, the HIV entry receptor CD4 is 
expressed by both resting (naïve) and activated helper T-cells, as well as terminally 
differentiated macrophages, a range of cells with markedly different metabolic programmes. 
In this review, we describe how HIV accessory proteins enable the virus to overcome these 
challenges by manipulating the metabolism of nucleotides, glucose, amino acids and lipids. 
We discuss cellular restriction factors which patrol metabolic pathways required for viral 
replication, and focus on recent discoveries highlighting HIV-mediated remodelling of the 
plasma membrane and interference with the T-cell nutrient supply.  
Expansion of the nucleotide pool  
Like all retroviruses, HIV encodes reverse transcriptase to generate complementary ssDNA 
from its positive-sense ssRNA genome, utilising cellular deoxynucleotide triphosphates 
(dNTPs) as substrates for DNA polymerisation. This metabolic bottleneck is exploited 
therapeutically by nucleoside/nucleotide and non-nucleoside reverse transcriptase inhibitors, 
which have formed the backbone of anti-retroviral drug therapy since zidovudine (AZT) was 
approved for the treatment of HIV in 1987. Productive HIV-1 infection in resting primary 
CD4+ T-cells and myeloid cells is inhibited at the level of reverse transcription by the scarcity 
of intracellular dNTPs (reviewed in [3]). Low concentrations of dNTPs are maintained by the 
recently described deoxynucleotide phosphohydrolase SAMHD1, which hydrolyses dNTPs 
to deoxynucleosides and free triphosphates, and therefore acts as a metabolic restriction 
factor [4,5]. Conversely, an expanded dNTP pool is characteristic of activated T-cells and 
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transformed/cancerous cell lines, enabling cellular DNA replication and relieving the block to 
reverse transcription [3]. 
Vpx of HIV-2 targets SAMHD1 for ubiquitin-dependent proteasomal degradation and, when 
incorporated into virions, overcomes the block to HIV reverse transcription in resting T-cells 
and myeloid cells [4,6,7]. Vpx is paralogous to Vpr, and Vpr variants of most primate 
lentiviruses lacking Vpx demonstrate species-specific antagonism of SAMHD1 [8].  This 
activity was surrendered by the cross-species transmission and recombination event that 
generated SIVcpz, and has not been reacquired by viruses of the SIVcpz/HIV-1 lineage [9].  
The absence of SAMHD1 antagonism in HIV-1 may have been partially compensated by the 
enhanced affinity (low Km) of HIV-1 reverse transcriptase for dNTPs [10], but it is also 
possible that the avoidance of productive replication in professional antigen presenting cells 
is itself an adaptive strategy for immune evasion.  
Induction of glycolysis 
As well as increasing dNTP availability, T-cell activation results in profound upregulation of 
glucose uptake and glycolytic flux, a process similar to oncogenic transformation (reviewed 
in [11] and [12]). As with cancer cells, aerobic glycolysis provides ATP, NADPH and the 
molecular building blocks for cellular biomass [13], and glycolysis is required to support the 
replication of a range of viruses (reviewed in [14] and [15]). Similarly, HIV infection of primary 
T-cells enhances glucose uptake and glycolytic flux [16,17], and the cell surface glucose 
transporter GLUT1 is required for both T-cell activation and efficient HIV replication [18,19]. 
The mechanism by which HIV enhances glycolysis has not been elucidated. However, it 
appears to be specific for primary T-cells, because enhanced glycolysis was not observed in 
HIV-infected Jurkat or CEM-SS (T-cell) or U937/U1 (monocyte/macrophage) models [16,17], 
and unlike T-cell activation, does not reflect increased expression of GLUT1 at the plasma 
membrane [17].  
Cutting the amino acid supply 
Whilst facilitating HIV replication, T-cell activation also triggers activation-induced cell death 
(AICD), limiting the life-span of infected cells [20]. Likewise, whilst glucose starvation inhibits 
virus production, it also prolongs survival of infected cells [17].  HIV-1 replication in vivo is 
therefore likely to be favoured by intermediate levels of T-cell activation [21], and Nef 
modulates signalling from the T-cell receptor (TCR) at several levels [22]. Attention has 
focussed on downregulation of the TCR-CD3 T-cell receptor complex by Nef variants of non-
pathogenic SIVs, which may limit immune activation by reducing AICD and inflammatory 
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cytokine release from infected cells [20]. Conversely, the ability to downregulate TCR-CD3 is 
attenuated in Nef variants of HIV-1 and most Vpu-containing primate lentiviruses [20],  
We recently used Tandem Mass Tag (TMT)-based plasma membrane proteomics to gain a 
comprehensive, unbiased overview of global changes in the cell surface landscape of HIV-1-
infected T-cells, including expression timecourses of >800 plasma membrane proteins [23]. 
As well as HIV-mediated downregulation of numerous immunoreceptors with important 
functions in T-cell activation, we identified downregulation of a range of transmembrane 
transporters without well-characterised roles in the immune system, particularly amino acid 
transporters. Amongst these, the System A transporter SNAT1 is specifically targeted for 
destruction by Vpu, and phylogenetic analysis has shown that the ability to downregulate 
SNAT1 arose in Vpu variants from the lineage of SIVcpz/HIV-1 viruses which gave rise to 
pandemic HIV-1. Since a correlation is observed between the presence of Vpu and the rate 
of disease progression in natural HIV-1/2 and experimental SHIV (SIV/HIV-1) infections, 
SNAT1 downregulation may therefore be important for the enhanced pathogenicity of HIV-1 
[24-27]. Many γ-retroviruses use amino acid transporters as their principal entry receptors 
[28], and some viruses (including HCMV) induce and rely on glutaminolysis for virus 
production and/or host cell survival [14]. Nonetheless, to our knowledge, downregulation of 
SNAT1 by Vpu is the first example of viral antagonism of amino acid metabolism to be 
defined at the molecular level.  
SNAT1 is dramatically upregulated at the surface of activated primary human CD4+ T-cells 
and, although best known as a neuronal glutamine transporter, in T-cells mediates 
quantitatively important transport of alanine, rather that glutamine ([23] and unpublished 
data). Whilst alanine is a non-essential amino acid, uptake of extracellular alanine by System 
A transport is required to maintain the intracellular pool of free alanine, explaining why a 
supply of exogenous alanine is required for optimal T-cell mitogenesis [29,30]. Vpu-mediated 
targeting of SNAT1, amongst all possible amino transporters, implies a specific role in HIV 
replication and T-cell metabolism. It is plausible that alanine starvation specifically 
contributes to a “partially activated” T-cell phenotype, favourable for HIV-replication.  
By modulating the composition of the tRNA pool of HIV-1-infected cells, the IFN-inducible 
restriction factor SLFN11 exploits unusual HIV codon bias to specifically inhibit viral (but not 
cellular) protein synthesis [31]. How SLFN11 differentially regulates specific tRNAs is 
unknown, and no viral antagonist has been identified. It remains to be determined whether 
this process (which operates at the tRNA level) intersects with antagonism of SNAT1 or 
other amino acid transporters (which operates at the amino acid level). However, the 
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unusual A-rich nucleotide composition of the HIV genome has long been recognised, and is 
known to result in biased amino acid composition of HIV proteins [32].  
Antagonism of SERINC-mediated restriction 
As well as downregulation of SNAT1 by Vpu, we also found downregulation of SERINC3 and 
SERINC5 by the accessory protein Nef [23], and these proteins were independently 
identified as potent HIV-1 restriction factors using orthogonal approaches [33,34]. Whilst 
poorly characterised, SERINC proteins enhance incorporation of serine into membrane 
phospholipids when over-expressed in E. coli and COS cells, and are therefore proposed to 
carry serine molecules into the hydrophobic milieu of lipid bilayers for synthesis of 
phosphatidylserine [35]. It is not currently known whether modulation of phosphatidylserine 
metabolism is required for SERINC-mediated restriction of HIV-1. However, the SERINC-
mediated block to virion infectivity appears to impact viral fusion pore formation or expansion 
[33,34], a bioenergetically costly process sensitive to phospholipid membrane composition 
[36]. HIV-1 virions are enriched in phosphatidylserine [37-39], exogenous phosphatidylserine 
or phosphatidylserine incorporated into enveloped virions regulates the infectivity of 
numerous viruses including HIV-1 [40-43], and the phosphatidylserine-binding protein TIM-1 
inhibits release of HIV-1 virions from the cell surface [44]. Together with SAMHD1 and 
SLFN11, SERINC proteins may therefore represent a third class of metabolic restriction 
factors.  
Interference with cholesterol efflux 
In addition to phosphatidylserine, HIV virions are enriched in cholesterol, reflecting viral 
budding from raft-like lipid microdomains [37-39]. Membrane recruitment and multimerisation 
of Gag is dependent on protein-lipid interactions, and leads to cholesterol-dependent 
reorganisation of lipid rafts and tetraspanin-enriched microdomains [45,46].  Treating 
producer cells with cholesterol-depleting agents impairs Gag assembly and HIV infectious 
virus production [47,48], and Nef increases cholesterol levels in macrophages by depleting 
the ABCA1 cholesterol efflux transporter, enhancing lipid raft formation and virion infectivity 
[49-52]. Like induction of glycolysis, Nef-mediated modulation of lipid metabolism is likely to 
be cell-type specific, because ABCA1 expression in vivo is seen in macrophages [53], but 
Nef has also been reported to induce expression of genes involved in cholesterol synthesis 
and uptake in T-cells [54].  
Dysregulation of iron metabolism  
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As well as downregulating SERINC3/5, ABCA1 and its canonical substrates CD4 and MHC-
Ia, Nef has also been reported to downregulate the non-classical MHC-Ib protein HFE [55]. 
Mutations in HFE cause dysregulation of iron homeostasis in hereditary haemochromatosis, 
and infection of macrophages with HIV led to Nef-dependent accumulation of intracellular 
iron [55]. HFE downregulation is not conserved across different HIV/SIV Nef variants [56], 
however, and the transferrin receptor may be downregulated [55,57] or upregulated [56] 
depending on the HIV/SIV Nef variants and cell type used. We saw downregulation of the 
transferrin receptor in HIV-infected T-cells, but this effect was Nef independent, and also 
seen in the presence of reverse transcriptase inhibitors [23]. Interference with iron 
metabolism by HIV is therefore likely to be pleiotropic and cell type dependent, and the 
biological significance remains to be determined.  
Conclusions  
HIV encodes accessory proteins which regulate the supply of intracellular metabolites, 
enabling reverse transcription and fine-tuning T-cell activation to optimise viral replication in 
vivo. By encoding 2 accessory proteins (Nef and Vpu) which specialise in the regulation of 
cell surface proteins, the virus is particularly well placed to modulate flux of small molecules 
across the plasma membrane. Differential regulation of amino acid transport in CD4+ T-cells 
is increasingly recognised to be crucial in shaping the immune response [58,59]. The study 
of pathways targeted by HIV therefore offers unique insights into both viral pathogenesis and 
critical aspects of immunobiology. 
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Figure 1.  Evolutionary origins of the HIV accessory proteins 
Indicative phylogenetic relationships of selected primate lentiviruses (left panel) and genomic 
structures of HIV-1 and HIV-2 (right panels) are shown. Viruses encoding Vpr (circles), Vpx 
(squares) and Vpu (triangles) are indicated, and variants able to antagonise SAMHD1 (Vpr 
or Vpx; red) and SNAT1 (Vpu; green) are highlighted. Almost all HIV infections are caused 
by HIV-1 group M viruses, which arose from chimpanzee SIVcpz by cross-species 
transmission in the Congo river basin in the early 1900s [60]. SIVcpz was itself derived from 
recombination between red capped mangabey SIVrcm and an ancestral Vpu-containing SIV 
related to the modern guenon monkey SIVgsn, SIVmus and SIVmon viruses (SIVguenon; reviewed 
in [61]). This recombination endowed SIVcpz/HIV-1 viruses with Vpu, but restructuring of the 
C-terminus of Vif to allow antagonism of human APOBEC3G resulted in loss of Vpx [9]. 
Downregulation of SNAT1 is restricted to Vpu variants of HIV-1 group M viruses and some 
SIVcpz/HIV-1 group N viruses [23]. A minority of HIV infections are caused by HIV-2 viruses, 
which arose from sooty mangabey monkey SIVsmm by multiple cross-species transmissions 
in West Africa, and therefore encode Vpx but not Vpu [61]. Regions of HIV-1/2 derived from 
mangabey SIVrcm/smm (blue) and guenon monkey SIVguenon (tan) viruses are highlighted. All 
primate lentiviruses encode Vif and Nef, and Vif is also found in other non-primate lentiviral 
lineages. Adapted from published phylogenetic trees [8,9,23,61] and genomic maps for HIV-
1 HXB2 and HIV-2 BEN available from www.hiv.lanl.gov. LTR, long terminal repeat.  
Figure 2. Metabolic regulation of the HIV replication cycle 
Host factors regulating metabolic pathways required for HIV replication (steps 1-7) are 
shown (blue) with the metabolic restriction factors SAMHD1 and SLFN11 highlighted (red 
borders). Viral accessory proteins Vpx, Vpu and Nef (beige) antagonise key host factors to 
overcome restriction and optimise the intracellular environment for viral replication. SAMHD1 
inhibits reverse transcription of the viral genome by reducing the availability of dNTPs, and is 
targeted for degradation by Vpx [4-7]. SLFN11 inhibits codon-usage-dependent viral protein 
synthesis by regulating the composition of the tRNA pool [31]. Downregulation of SNAT1 by 
Vpu restricts the supply of exogenous alanine and inhibits T-cell mitogenesis [23], but the 
specific downstream consequences of alanine restriction (for example, on the charged tRNA 
pool) remain to be determined. SERINC3 and SERINC5 are recently described restriction 
factors, antagonised by Nef, that regulate serine incorporation into membrane phospholipids 
[23,33-35]. Whether this activity is required for restriction of HIV remains to be determined. 
ssRNA, single-stranded RNA; dsDNA, double-stranded DNA; dNTPs, deoxynucleotide 
triphosphates; mRNAs, messenger RNAs; gRNA, genomic RNA; tRNAs, transfer RNAs. 
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Highlights  
 Host restriction factors exploit metabolic dependencies to limit HIV replication 
 HIV accessory proteins manipulate cellular metabolism and counteract restriction 
 Conflict between SAMHD1 and Vpx regulates the dNTP pool for reverse transcription 
 Vpu and Nef downregulate cell surface transporters to control the nutrient supply 
 Targeting by HIV identifies critical pathways in T-cell immunometabolism 
 
